PE20060296A1 - Composicion farmaceutica que contiene interferon muteina - Google Patents

Composicion farmaceutica que contiene interferon muteina

Info

Publication number
PE20060296A1
PE20060296A1 PE2005000660A PE2005000660A PE20060296A1 PE 20060296 A1 PE20060296 A1 PE 20060296A1 PE 2005000660 A PE2005000660 A PE 2005000660A PE 2005000660 A PE2005000660 A PE 2005000660A PE 20060296 A1 PE20060296 A1 PE 20060296A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
composition containing
mutein
containing interferon
interferon
Prior art date
Application number
PE2005000660A
Other languages
English (en)
Inventor
Georg Groetzbach
Joachim-Friedrich Kapp
Uwe Kuehl
Olaf Sowade
Claus-Steffen Stuerzebecher
Heinz-Peter Schultheiss
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20060296A1 publication Critical patent/PE20060296A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE UN INTERFERON A o B MUTEINA EL CUAL TIENE UNA CISTEINA EN POSICION 17 SUPRIMIDA O REEMPLAZADA POR UN AMINOACIDO NEUTRO SELECCIONADO DE SERINA, TREONINA, GLICINA, ALANINA, VALINA, LEUCINA, ENTRE OTROS; EN UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE 30-500 mcg. DICHO INTERFERON ES MONOMERICO, PEGILADO Y ESTA SOLUBILIZADO EN UNA FORMULACION CUYA FUERZA IONICA ES DE APROXIMADAMENTE DE 1 A 100 mM, SIENDO EL PH DE 2 A 5 APROXIMADAMENTE. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE MIOCARDIOPATIA Y DISFUNCION ENDOTELIAL
PE2005000660A 2004-06-09 2005-06-09 Composicion farmaceutica que contiene interferon muteina PE20060296A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57902404P 2004-06-09 2004-06-09

Publications (1)

Publication Number Publication Date
PE20060296A1 true PE20060296A1 (es) 2006-05-25

Family

ID=35503655

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000660A PE20060296A1 (es) 2004-06-09 2005-06-09 Composicion farmaceutica que contiene interferon muteina

Country Status (7)

Country Link
US (1) US20050276785A1 (es)
AR (1) AR049143A1 (es)
PA (1) PA8636501A1 (es)
PE (1) PE20060296A1 (es)
TW (1) TW200612981A (es)
UY (1) UY28954A1 (es)
WO (1) WO2005120540A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2621511T3 (es) * 2007-04-06 2017-07-04 Takeda Vaccines, Inc. Métodos y composiciones para virus vivos atenuados
WO2008127711A2 (en) * 2007-04-11 2008-10-23 Pestka Biomedical Laboratories, Inc. Interferons of rhesus and cynomolgus origin and uses thereof
US11351118B2 (en) 2016-12-21 2022-06-07 Arbutus Biopharma Corporation Methods for ameliorating infusion reactions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
DE69636112T2 (de) * 1995-08-30 2006-12-14 Toray Industries, Inc. Verfahren zum testen von myocarditis und cardiomyopathie
SK287491B6 (sk) * 1998-10-16 2010-11-08 Biogen Idec Ma Inc. Fúzne proteíny interferónu- beta-1a a ich použitie
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
JP2005506957A (ja) * 2001-06-11 2005-03-10 トランジション・セラピューティックス・インコーポレーテッド ウイルス性、増殖性および炎症性の疾患の治療のためにビタミンｂ１２およびインターフェロンを用いた複合治療

Also Published As

Publication number Publication date
US20050276785A1 (en) 2005-12-15
WO2005120540A3 (en) 2006-05-18
AR049143A1 (es) 2006-06-28
PA8636501A1 (es) 2006-07-03
UY28954A1 (es) 2006-01-31
TW200612981A (en) 2006-05-01
WO2005120540A2 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
PE20000560A1 (es) Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica
PE20020127A1 (es) Interleuquina 2 estabilizada
ES2185595T3 (es) Peptidos antivirales modificados y sus composiciones para la prevencion y/o el tratamiento de infecciones viricas.
NZ593190A (en) Factor viii formulations
ATE509618T1 (de) Nanoteilchenförmige zusammensetzungen mit einem peptid als oberflächenstabilisator
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
PE20120021A1 (es) Mutantes fgf21
HRP20110242T1 (hr) Formulacija s fuzijskim proteinom glp-1-fc
AR027391A1 (es) Composiciones farmaceuticas de toxina botulinica
PE20060880A1 (es) Conjugados de polipeptido y un pentasacarido que tienen propiedades farmacocineticas mejoradas
EA200501810A1 (ru) Композиция конъюгированного лекарственного средства
CL2004000409A1 (es) Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
EA200800233A1 (ru) Композиция иммуноконьюгата
WO2007014391A3 (en) Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
AR070588A1 (es) Composiciones que contienen aminoacido basico y sal carbonato soluble
BRPI0511005A (pt) peptìdeos oligoméricos e seu uso para o tratamento de infecções por hiv
AR056137A1 (es) Un conjugado peptido inmunoglobulina y su uso como antiviral
DE602004015725D1 (de) Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
DE602008004656D1 (de) Zusammensetzung zur transmukosalen abgabe von polypeptiden
BRPI0407533A (pt) proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.
DK1641820T3 (da) Fra RasGap afledt peptid til selektiv at dræbe kræftceller
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
PE20060296A1 (es) Composicion farmaceutica que contiene interferon muteina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal